Vitamin C for COVID-19
6th treatment shown to reduce risk in
September 2020
No treatment is 100% effective. Protocols
combine complementary and synergistic treatments. * >10%
efficacy in meta analysis with ≥3 clinical studies.
4,100+ studies for
60+ treatments. c19early.org
|
risk of death, 27.8% lower, HR 0.72, p = 0.19, treatment 190, control 194, combined.
|
risk of death, 27.5% lower, HR 0.72, p = 0.34, treatment 84, control 97, inverted to make HR<1 favor treatment, LOVIT-COVID critical.
|
risk of death, 28.1% lower, HR 0.72, p = 0.37, treatment 106, control 97, inverted to make HR<1 favor treatment, LOVIT-COVID non-critical.
|
risk of death, 16.3% higher, HR 1.16, p = 0.22, inverted to make HR<1 favor treatment, REMAP-CAP critical.
|
risk of death, 26.6% higher, HR 1.27, p = 0.19, inverted to make HR<1 favor treatment, REMAP-CAP non-critical.
|
risk of death, 6.4% higher, HR 1.06, p = 0.47, treatment 1,032, control 528, inverted to make HR<1 favor treatment, combined trials, critical, day 90.
|
risk of death, 7.5% higher, HR 1.08, p = 0.56, treatment 454, control 563, inverted to make HR<1 favor treatment, combined trials, non-critical, day 90.
|
risk of death, 6.4% higher, HR 1.06, p = 0.61, treatment 1,032, control 528, inverted to make HR<1 favor treatment, combined trials, critical, day 28.
|
risk of death, 6.4% higher, HR 1.06, p = 0.71, treatment 454, control 563, inverted to make HR<1 favor treatment, non-critical, day 28.
|
risk of mechanical ventilation, 35.1% higher, HR 1.35, p = 0.04, treatment 1,032, control 528, inverted to make HR<1 favor treatment, combined trials, critical.
|
risk of mechanical ventilation, 69.5% higher, HR 1.69, p = 0.008, treatment 454, control 563, inverted to make HR<1 favor treatment, combined trials, non-critical.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |